Heartflow (HTFL) CMO trades 65,153 shares under Rule 10b5-1 plan
Rhea-AI Filing Summary
Heartflow, Inc. Chief Medical Officer Campbell Rogers reported option exercises and share sales in HTFL stock. On February 12, 2026, he exercised multiple stock options, converting them into common shares at exercise prices of $2.22 and $8.33 per share.
On the same date, he then sold 65,153 shares of common stock in open-market transactions at a weighted average price of $24.4883 per share, under a Rule 10b5-1 trading plan adopted on September 12, 2025. After these transactions, he held 76,034 shares directly, with additional indirect holdings reported in several family and personal trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
11 txns
Insider
Rogers Campbell
Role
Chief Medical Officer
Sold
65,153 shs ($1.60M)
Approx. gross sale proceeds
$1.60M
Approx. exercise cost
$391K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 39,709 | $0.00 | $0.00 |
| Exercise | Stock Option | 19,401 | $0.00 | $0.00 |
| Exercise | Stock Option | 7,906 | $0.00 | $0.00 |
| Exercise | Common Stock | 19,401 | $2.22 | $43K |
| Exercise | Common Stock | 39,709 | $8.33 | $331K |
| Exercise | Common Stock | 7,906 | $2.22 | $18K |
| Sale | Common Stock | 65,153 | $24.4883 | $1.60M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 208,527 shares (Direct);
Common Stock — 76,034 shares (Direct);
Common Stock — 22,615 shares (Indirect, By Campbell Rogers 2019 Irrevocable Trust);
Common Stock — 46,159 shares (Indirect, By CR Asset Protection Trust of 2023);
Common Stock — 26,012 shares (Indirect, By Spouse's Trust);
Common Stock — 50,754 shares (Indirect, By The Campbell Rogers Revocable Trust)
Footnotes (6)
- F1. The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- F2. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- F3. Includes the sale of 17,538 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- F4. This transaction was executed in multiple trades at price ranging from $22.90 to $26.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. These stock options are fully exercisable.
- F6. The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
